Screener
Viridian Therapeutics, Inc. VRDN Interest Expense
Interest Expense at other companies
Other financials
Where this comes from
Reported directly by Viridian Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:InterestExpenseNonoperating.
The source filing: Viridian Therapeutics, Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 7:31 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001590750-26-000018
FAQ
- What is Viridian Therapeutics, Inc.'s interest expense?
- Viridian Therapeutics, Inc. (VRDN) reported interest expense of $8.31M in Q2 2026.
- How has Viridian Therapeutics, Inc.'s interest expense changed year-over-year?
- Viridian Therapeutics, Inc.'s interest expense increased by 1516.1% year-over-year, from $514K to $8.31M.
- What is the long-term trend for Viridian Therapeutics, Inc.'s interest expense?
- Over 4 years (2021 to 2025), Viridian Therapeutics, Inc.'s interest expense has grown at a 535.9% compound annual growth rate (CAGR), from $3K to $4.91M.
- What does interest expense mean?
- Cost of borrowing — interest paid or accrued on bonds, bank loans, credit facilities, finance leases, and other debt obligations.
Ask your AI about Viridian Therapeutics, Inc.'s interest expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude